Insomnia Drugs

Insomnia Drugs Comprehensive Study by Type (Prescription-based Drugs, OTC Drugs, Herbal Drugs), Application (Hospitals, Clinics, Research Centres, Others), Distribution Channel (Retail Pharmacies, Online Pharmacies), Intake Form (Tablets, Injections, Capsules) Players and Region - Global Market Outlook to 2030

Insomnia Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Insomnia Drugs
Insomnia is also known as somnipathy or Sleep disorder is a medical disorder in which the patient experience difficulty in sleep maintenance or sleep initiation. For insomnia there are several symptoms which include mental, physical, social, and emotional functions. Lack of sleep has a negative impact on the health of a person. The prevalence of insomnia has been significantly increased which is a primary factor fostering the market growth. Reportedly, in the United States, over 75% of people aged between 20 and 59 years have sleeping difficulties frequently.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR5.7%


Key players are adopting numerous strategies to gain market attention and to increase their market share, this strategy can be listed as increasing product portfolio, making partnerships to adopt certain technologies, and acquiring small players to finish the competition in the future. As well as investing money in the R&D sector to make technical upgrades to the product. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Insomnia Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Sanofi (France), Merck Sharp & Dohme Corporation (United States), GlaxoSmithKline (United Kingdom), Koninklijke Philips N.V. (Netherlands), Takeda Pharmaceutical Company (Japan), Leva Pharmaceutical Industries (Pakistan), Cardinal Health, Inc. (United States), Becton Dickson and Company (United States) and Natus Medicalorporated (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Insomnia Drugs market by Type (Prescription-based Drugs, OTC Drugs and Herbal Drugs), Application (Hospitals, Clinics, Research Centres and Others) and Region.



On the basis of geography, the market of Insomnia Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Retail Pharmacies will boost the Insomnia Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Intake Form, the sub-segment i.e. Tablets will boost the Insomnia Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Introduction of Home Sleep Test Kits and Wearable Monitors, Advent of Continuous Positive Airway Pressure (CPAP) Therapy and Affordable Reimbursement Scenario for Drugs prescribed in Insomnia Treatment

Market Growth Drivers:
Increasing Incidence of Depression & Medical Disorder, Rising Geriatric Population and Associated Sleep Disorder and High Usage of Sleeping Aid Devices and Growing Healthcare Facilities

Challenges:
Patent Expiration of Insomnia Treatment Drugs

Restraints:
Side Effects Associated with the Drug used to Treat Insomnia Disorder

Opportunities:
Rising Investment on Research and Development of Drugs for the Insomnia Disorder

Market Leaders and their expansionary development strategies
In September 2020, Idorsia Ltd received US FDA approval for QUVIVIQ (daridorexant) for the treatment of adults with insomnia and has entered into a commercial relationship with Syneos Health for the US commercialization of the drug.
In June 2020, Eisai Co., Ltd. launched a new insomnia drug DAYVIGO™ (lemborexant) CIV in the United States as a treatment option for adults with insomnia.
November 2018, the European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi.

Key Target Audience
Insomnia Drugs Manufacturer, Industry Associations, Potential Investors, Hospitals, Research Centre, Supplier, Traders & Distributors, Government and Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Prescription-based Drugs
  • OTC Drugs
  • Herbal Drugs
By Application
  • Hospitals
  • Clinics
  • Research Centres
  • Others
By Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies

By Intake Form
  • Tablets
  • Injections
  • Capsules

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Depression & Medical Disorder
      • 3.2.2. Rising Geriatric Population and Associated Sleep Disorder
      • 3.2.3. High Usage of Sleeping Aid Devices and Growing Healthcare Facilities
    • 3.3. Market Challenges
      • 3.3.1. Patent Expiration of Insomnia Treatment Drugs
    • 3.4. Market Trends
      • 3.4.1. Introduction of Home Sleep Test Kits and Wearable Monitors
      • 3.4.2. Advent of Continuous Positive Airway Pressure (CPAP) Therapy
      • 3.4.3. Affordable Reimbursement Scenario for Drugs prescribed in Insomnia Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Insomnia Drugs, by Type, Application, Distribution Channel, Intake Form and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Insomnia Drugs (Value)
      • 5.2.1. Global Insomnia Drugs by: Type (Value)
        • 5.2.1.1. Prescription-based Drugs
        • 5.2.1.2. OTC Drugs
        • 5.2.1.3. Herbal Drugs
      • 5.2.2. Global Insomnia Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Research Centres
        • 5.2.2.4. Others
      • 5.2.3. Global Insomnia Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Retail Pharmacies
        • 5.2.3.2. Online Pharmacies
      • 5.2.4. Global Insomnia Drugs by: Intake Form (Value)
        • 5.2.4.1. Tablets
        • 5.2.4.2. Injections
        • 5.2.4.3. Capsules
      • 5.2.5. Global Insomnia Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Insomnia Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck Sharp & Dohme Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Koninklijke Philips N.V. (Netherlands)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takeda Pharmaceutical Company (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Leva Pharmaceutical Industries (Pakistan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cardinal Health, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Becton Dickson and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Natus Medicalorporated (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Insomnia Drugs Sale, by Type, Application, Distribution Channel, Intake Form and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Insomnia Drugs (Value)
      • 7.2.1. Global Insomnia Drugs by: Type (Value)
        • 7.2.1.1. Prescription-based Drugs
        • 7.2.1.2. OTC Drugs
        • 7.2.1.3. Herbal Drugs
      • 7.2.2. Global Insomnia Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Research Centres
        • 7.2.2.4. Others
      • 7.2.3. Global Insomnia Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Retail Pharmacies
        • 7.2.3.2. Online Pharmacies
      • 7.2.4. Global Insomnia Drugs by: Intake Form (Value)
        • 7.2.4.1. Tablets
        • 7.2.4.2. Injections
        • 7.2.4.3. Capsules
      • 7.2.5. Global Insomnia Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Insomnia Drugs: by Type(USD Million)
  • Table 2. Insomnia Drugs Prescription-based Drugs , by Region USD Million (2018-2023)
  • Table 3. Insomnia Drugs OTC Drugs , by Region USD Million (2018-2023)
  • Table 4. Insomnia Drugs Herbal Drugs , by Region USD Million (2018-2023)
  • Table 5. Insomnia Drugs: by Application(USD Million)
  • Table 6. Insomnia Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 7. Insomnia Drugs Clinics , by Region USD Million (2018-2023)
  • Table 8. Insomnia Drugs Research Centres , by Region USD Million (2018-2023)
  • Table 9. Insomnia Drugs Others , by Region USD Million (2018-2023)
  • Table 10. Insomnia Drugs: by Distribution Channel(USD Million)
  • Table 11. Insomnia Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Insomnia Drugs Online Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Insomnia Drugs: by Intake Form(USD Million)
  • Table 14. Insomnia Drugs Tablets , by Region USD Million (2018-2023)
  • Table 15. Insomnia Drugs Injections , by Region USD Million (2018-2023)
  • Table 16. Insomnia Drugs Capsules , by Region USD Million (2018-2023)
  • Table 17. South America Insomnia Drugs, by Country USD Million (2018-2023)
  • Table 18. South America Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 19. South America Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 20. South America Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 21. South America Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 22. Brazil Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 23. Brazil Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 24. Brazil Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 25. Brazil Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 26. Argentina Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 27. Argentina Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 28. Argentina Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 29. Argentina Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 30. Rest of South America Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 33. Rest of South America Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 34. Asia Pacific Insomnia Drugs, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 38. Asia Pacific Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 39. China Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 40. China Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 41. China Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 42. China Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 43. Japan Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 44. Japan Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 45. Japan Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 46. Japan Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 47. India Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 48. India Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 49. India Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 50. India Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 51. South Korea Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 52. South Korea Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 53. South Korea Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 54. South Korea Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 55. Taiwan Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 56. Taiwan Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 57. Taiwan Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 58. Taiwan Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 59. Australia Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 60. Australia Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 61. Australia Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 62. Australia Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 67. Europe Insomnia Drugs, by Country USD Million (2018-2023)
  • Table 68. Europe Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 69. Europe Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 70. Europe Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 71. Europe Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 72. Germany Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 73. Germany Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 74. Germany Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 75. Germany Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 76. France Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 77. France Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 78. France Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 79. France Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 80. Italy Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 81. Italy Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 82. Italy Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 83. Italy Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 84. United Kingdom Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 87. United Kingdom Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 88. Netherlands Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 89. Netherlands Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 90. Netherlands Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 91. Netherlands Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 92. Rest of Europe Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 95. Rest of Europe Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 96. MEA Insomnia Drugs, by Country USD Million (2018-2023)
  • Table 97. MEA Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 98. MEA Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 99. MEA Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 100. MEA Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 101. Middle East Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 102. Middle East Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 103. Middle East Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 104. Middle East Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 105. Africa Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 106. Africa Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 107. Africa Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 108. Africa Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 109. North America Insomnia Drugs, by Country USD Million (2018-2023)
  • Table 110. North America Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 111. North America Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 112. North America Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 113. North America Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 114. United States Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 115. United States Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 116. United States Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 117. United States Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 118. Canada Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 119. Canada Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 120. Canada Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 121. Canada Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 122. Mexico Insomnia Drugs, by Type USD Million (2018-2023)
  • Table 123. Mexico Insomnia Drugs, by Application USD Million (2018-2023)
  • Table 124. Mexico Insomnia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 125. Mexico Insomnia Drugs, by Intake Form USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Insomnia Drugs: by Type(USD Million)
  • Table 137. Insomnia Drugs Prescription-based Drugs , by Region USD Million (2025-2030)
  • Table 138. Insomnia Drugs OTC Drugs , by Region USD Million (2025-2030)
  • Table 139. Insomnia Drugs Herbal Drugs , by Region USD Million (2025-2030)
  • Table 140. Insomnia Drugs: by Application(USD Million)
  • Table 141. Insomnia Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 142. Insomnia Drugs Clinics , by Region USD Million (2025-2030)
  • Table 143. Insomnia Drugs Research Centres , by Region USD Million (2025-2030)
  • Table 144. Insomnia Drugs Others , by Region USD Million (2025-2030)
  • Table 145. Insomnia Drugs: by Distribution Channel(USD Million)
  • Table 146. Insomnia Drugs Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 147. Insomnia Drugs Online Pharmacies , by Region USD Million (2025-2030)
  • Table 148. Insomnia Drugs: by Intake Form(USD Million)
  • Table 149. Insomnia Drugs Tablets , by Region USD Million (2025-2030)
  • Table 150. Insomnia Drugs Injections , by Region USD Million (2025-2030)
  • Table 151. Insomnia Drugs Capsules , by Region USD Million (2025-2030)
  • Table 152. South America Insomnia Drugs, by Country USD Million (2025-2030)
  • Table 153. South America Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 154. South America Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 155. South America Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 156. South America Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 157. Brazil Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 158. Brazil Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 159. Brazil Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 160. Brazil Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 161. Argentina Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 162. Argentina Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 163. Argentina Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 164. Argentina Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 165. Rest of South America Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 166. Rest of South America Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 167. Rest of South America Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 168. Rest of South America Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 169. Asia Pacific Insomnia Drugs, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 171. Asia Pacific Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 172. Asia Pacific Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 173. Asia Pacific Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 174. China Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 175. China Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 176. China Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 177. China Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 178. Japan Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 179. Japan Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 180. Japan Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 181. Japan Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 182. India Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 183. India Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 184. India Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 185. India Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 186. South Korea Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 187. South Korea Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 188. South Korea Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 189. South Korea Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 190. Taiwan Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 191. Taiwan Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 192. Taiwan Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 193. Taiwan Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 194. Australia Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 195. Australia Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 196. Australia Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 197. Australia Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 202. Europe Insomnia Drugs, by Country USD Million (2025-2030)
  • Table 203. Europe Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 204. Europe Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 205. Europe Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 206. Europe Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 207. Germany Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 208. Germany Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 209. Germany Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 210. Germany Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 211. France Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 212. France Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 213. France Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 214. France Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 215. Italy Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 216. Italy Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 217. Italy Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 218. Italy Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 219. United Kingdom Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 220. United Kingdom Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 221. United Kingdom Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 222. United Kingdom Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 223. Netherlands Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 224. Netherlands Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 225. Netherlands Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 226. Netherlands Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 227. Rest of Europe Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 228. Rest of Europe Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 229. Rest of Europe Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 230. Rest of Europe Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 231. MEA Insomnia Drugs, by Country USD Million (2025-2030)
  • Table 232. MEA Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 233. MEA Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 234. MEA Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 235. MEA Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 236. Middle East Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 237. Middle East Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 238. Middle East Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 239. Middle East Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 240. Africa Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 241. Africa Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 242. Africa Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 243. Africa Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 244. North America Insomnia Drugs, by Country USD Million (2025-2030)
  • Table 245. North America Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 246. North America Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 247. North America Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 248. North America Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 249. United States Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 250. United States Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 251. United States Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 252. United States Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 253. Canada Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 254. Canada Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 255. Canada Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 256. Canada Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 257. Mexico Insomnia Drugs, by Type USD Million (2025-2030)
  • Table 258. Mexico Insomnia Drugs, by Application USD Million (2025-2030)
  • Table 259. Mexico Insomnia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 260. Mexico Insomnia Drugs, by Intake Form USD Million (2025-2030)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Insomnia Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Insomnia Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Insomnia Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Insomnia Drugs: by Intake Form USD Million (2018-2023)
  • Figure 8. South America Insomnia Drugs Share (%), by Country
  • Figure 9. Asia Pacific Insomnia Drugs Share (%), by Country
  • Figure 10. Europe Insomnia Drugs Share (%), by Country
  • Figure 11. MEA Insomnia Drugs Share (%), by Country
  • Figure 12. North America Insomnia Drugs Share (%), by Country
  • Figure 13. Global Insomnia Drugs share by Players 2023 (%)
  • Figure 14. Global Insomnia Drugs share by Players (Top 3) 2023(%)
  • Figure 15. Global Insomnia Drugs share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2023
  • Figure 19. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi (France) Revenue: by Geography 2023
  • Figure 21. Merck Sharp & Dohme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck Sharp & Dohme Corporation (United States) Revenue: by Geography 2023
  • Figure 23. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 25. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 26. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2023
  • Figure 27. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2023
  • Figure 29. Leva Pharmaceutical Industries (Pakistan) Revenue, Net Income and Gross profit
  • Figure 30. Leva Pharmaceutical Industries (Pakistan) Revenue: by Geography 2023
  • Figure 31. Cardinal Health, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Cardinal Health, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Becton Dickson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Becton Dickson and Company (United States) Revenue: by Geography 2023
  • Figure 35. Natus Medicalorporated (United States) Revenue, Net Income and Gross profit
  • Figure 36. Natus Medicalorporated (United States) Revenue: by Geography 2023
  • Figure 37. Global Insomnia Drugs: by Type USD Million (2025-2030)
  • Figure 38. Global Insomnia Drugs: by Application USD Million (2025-2030)
  • Figure 39. Global Insomnia Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 40. Global Insomnia Drugs: by Intake Form USD Million (2025-2030)
  • Figure 41. South America Insomnia Drugs Share (%), by Country
  • Figure 42. Asia Pacific Insomnia Drugs Share (%), by Country
  • Figure 43. Europe Insomnia Drugs Share (%), by Country
  • Figure 44. MEA Insomnia Drugs Share (%), by Country
  • Figure 45. North America Insomnia Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Sanofi (France)
  • Merck Sharp & Dohme Corporation (United States)
  • GlaxoSmithKline (United Kingdom)
  • Koninklijke Philips N.V. (Netherlands)
  • Takeda Pharmaceutical Company (Japan)
  • Leva Pharmaceutical Industries (Pakistan)
  • Cardinal Health, Inc. (United States)
  • Becton Dickson and Company (United States)
  • Natus Medicalorporated (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 211 Pages 52 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Insomnia Drugs Quantitative research analysis
Insomnia Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Sanofi (France), Merck Sharp & Dohme Corporation (United States), GlaxoSmithKline (United Kingdom), Koninklijke Philips N.V. (Netherlands), Takeda Pharmaceutical Company (Japan), Leva Pharmaceutical Industries (Pakistan), Cardinal Health, Inc. (United States), Becton Dickson and Company (United States) and Natus Medicalorporated (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Introduction of Home Sleep Test Kits and Wearable Monitors " is seen as one of major influencing trends for Insomnia Drugs Market during projected period 2023-2030.
The Insomnia Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Insomnia Drugs Report?

Have a Query? Click Here

Other Related Reports

Thrombin Comprehensive Study by Type (Bovine Thrombin, Human Thrombin, Recombinant Thrombin), Dosage Form (Powder Form, Solution Form), End User (Hospitals, Diagnostics Centers & Clinics, Ambulatory ...
$ 3450
Heavy Metal Poisoning Drugs Comprehensive Study by Type (ALN-TMP, Deferasirox, Deferoxamine Mesylate, Emeramide, Others), Application (Arsenic Toxicity, Chromium Toxicity, Copper Toxicity, Lead Toxic...
$ 3750
Pharmaceutical Robots Comprehensive Study by Type (Traditional Robots {Articulated, SCARA, Delta Parallel and Cartesian}, Collaborative Robots), Application (Picking and Packaging, Inspection of Drug...
$ 3450
Hypertension Drugs Comprehensive Study by Type (Systemic Hypertension Drugs, Pulmonary Hypertension Drugs), Application (Hospital Use, Clinic Use, Others), Distribution Channel (Retail Pharmacies, Ho...
$ 3750
High Blood Pressure Drugs Comprehensive Study by Type (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Vasodilators, Alpha Blockers, Re...
$ 3750
Nanoemulsion Comprehensive Study by Type (Nanocapsule, Lipid Nanocapsule, Nanosphere, Others), Application (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Antimicrobial, Anticancer, Anaesthetics, Ant...
$ 3750